Implications: Two novel potent and selective RSK inhibitors will now allow a full assessment of RSK's potential as a therapeutic target for oncology.
Kinase selectivity profiling was carried out by KinomeScan (Ambit/DiscoveRx,Fremont, CA).
Data are reported as 100 minus percent of control, where larger numbers indicate more complete binding.
pYB1 Quantification
A quantitative electochemiluminescence (ECL) assay was developed to measure cellular levels of YB1 protein phosphorylated at Ser102. This assay was built using ECL reagents from MesoScale Discovery (MSD, Rockville, MD). Specifically, cell lysate generated using RIPA lysis buffer (Sigma, R0278-500ml) was added to unblocked 96-well high bind ECL plates and incubated overnight at 4°C on a plate shaker. The following day, plates were washed with 1x wash buffer followed by two-hour room-temperature incubation with 10% BSA diluted in 1x tris-wash buffer (50nm Tris pH 7.5, 0.15M NaCl, 0.02% . Plates were then washed with 1x wash buffer followed by two-hour room temperature incubation with a phospho-specific Ser102 YB1 antibody (Cell Signaling Technologies; C34A2; 1.3ug/ml). Plates were washed again with 1x wash buffer and then incubated for two-hours at room temperature with a sulfo-tag goat anti-rabbit signaling antibody (MSD; 0.5 ug/ml). Plates underwent a final wash before addition of 1.5X MSD Read buffer and detection of the phospho-YB1 signal in a MSD Sector 6000 plate reader. We routinely ran this assay using a mouse BAF cell line engineered to express activated FGFR, but it is readily applicable to other cell lines with sufficient baseline phosphorylation of YB1. Although total YB1 levels were not affected by inhibitor treatment, we routinely normalized the phospho-YB1 signal to total YB1 signal for EC 50 calculation. Total YB1 was detected through the same protocol described for phospho-YB1, but utilized a total on January 18, 2018. © 2014 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on February 19, 2014 ; DOI: 10.1158/1541-7786.MCR- As a common shortcoming of many RSK inhibitors is their poor selectivity profile, we utilized KinomeScan TM kinase binding screening assays to assess the selectivity profiles of LJH685 and LJI308 binding to 96 kinases. LJH685 and LJI308 bound nearly 100% of RSK2 at 10µM concentration, but bound none of the other kinases to the same extent, suggesting good selectivity for RSK. Furthermore, when LJI308 was tested in an expanded panel of 442 kinases, it bound the targeted N-termini of remaining RSK isoforms, RSK1, RSK3 and RSK4 to similar extent (Table S1 ). Overall, only MEK4, S6K1, and HIPK1-3 bound either compound to the same degree. To determine whether the binding of LJI308 to MEK4, S6K1, and HIP kinases translates into inhibition of enzyme activity, we tested LJI308 in biochemical activity assays for these kinases. LJI308 inhibited S6K1 with an IC 50 of 0.8 μM, representing a 200 fold lower inhibition than that of RSK2. LJI308 inhibited MEK4 less than 50% at 10 μM and HIP kinase1 less than 50% at 1 μM. This suggests that none of these kinases are inhibited with similar potency as the RSK isoforms, and that LJH685 and LJI308 are exceptionally selective inhibitors of RSK1, 2, 3, and 4.
BI-D1870-AE was tested against the same panel of 96 kinases and resulted in RSK2 binding to 99.9%, while it bound type II receptor for bone morphogenetic protein (BMPR) kinase, Polo-like kinases (PLK1 and PLK3) and several other kinases, including aurora kinase (AURKB) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (PI3CG) to a similar extent as the on-target effect on RSK2 ( Figure 1B and Table S1 ). By this comparison, LJH685 and LJI308 have significantly improved specificity over BI-D1870-AE.
To confirm the binding site for LJH685 in RSK and to better understand its selectivity, we solved the crystal structure of LJH685 (Figure 2 , PDB ID code 4NUS). LJH685 bound RSK2 in a non-planar conformation where the three aromatic rings form a propeller shaped arrangement. Furthermore, the difluorophenol ring is binding to the gatekeeper area and is twisted 49 degrees from the plane of the pyridine ring. In most kinases, the area around the gatekeeper prefers substituents in the same plane as the hinge binding moiety. To accommodate the propeller arrangement, Phe212 of the DFG motif flips out in a conformation reminiscent of the classical type II, DFG-out orientation. However, Asp211 of the DFG blocks access to the hydrophobic pocket and interacts with the di-fluorophenyl ring and the catalytic Lys100. Thus, we propose that the non-planar shape of LJH685 and its conformational properties distinct from the currently available and commonly used inhibitor dihydropteridinone (BI-D1870) contribute to its significantly improved selectivity profile (manuscript in preparation). Furthermore, given the biochemical profile of structurally related molecules LJH685 and LJI308 and their mode of targeting RSK N-terminal kinase via interaction with the ATP binding site, these compounds are nearly identical with respect to RSK inhibition and are used interchangeably in further experiments.
LJH685 potently and selectively inhibits RSK in cells.
We tested the ability of these compounds to inhibit RSK in a cellular context. YB1's description as a direct substrate for RSK made it an excellent candidate cellular marker for RSK activity. Experiments using EGF-stimulated COS7 cells as a model system for active MAP kinase signaling confirmed that in that context, YB1 is directly phosphorylated on Ser102 by RSK ( Figure S1 ). We therefore used pSer102-YB1as a cellular marker for RSK and asked whether its phosphorylation in MDA-MB-231 cancer cells that bear activating mutations within the MAPK signaling pathway could be modulated by RSK inhibitors. As shown in Figure 3A , LJH685 efficiently reduced phosphorylation of YB1 at sub-micromolar concentrations and caused nearly complete inhibition at higher concentrations. In comparison, the C-terminal RSK (Figures 3 & 4) .
Because a number of other proteins have also been described as phosphorylated by RSK, we confirmed that phosphorylation of a second of these, the anti-apoptotic protein BAD at Ser112, is also inhibited by LJH685 at concentrations that correlate well with inhibition of pYB-1 ( Fig S2) .
We next compared LJH685 and LJI308 with additional inhibitors of the MAP kinase signaling pathway and the parallel PI3 kinase signaling pathway for their ability to inhibit phosphorylation of YB1. In these experiments, we used MDA-MB-231 and NCI-H358 (H358) cells which have KRAS mutations that activate MAPK signaling and represent established models for late stage invasive triple negative breast cancer and non-small cell lung carcinoma, respectively. The cells were treated with 10µM LJH685, LJI308, or 6µM FMK-PA for 4 hours.
In addition, inhibitors of MEK (PD0325901), ERK (I-9), AKT (MK2206) and two mTOR inhibitors targeting catalytic and allosteric domains of the molecule respectively (KU-0063794 and RAD001) were compared to LJH685 and LJI308 in this study system (15, (18) (19) (20) (21) . The doses were chosen based on previous data to give full target modulation by each compound (data not previous publications implicate AKT in YB1 activation (12, 13) , AKT inhibition did not affect YB1 phosphorylation, confirming the specificity of phospho-YB1 modulation by RSK in these cells (also see Figure S2 ). Surprisingly, in H358 cells inhibition of mTOR with either KU-0063794 or RAD001caused partial inhibition of YB1 phosphorylation. This suggests that in this cell line, mTOR can influence YB1 phosphorylation, either directly or via crosstalk with RSK ( Figure 3B , left panels).
Ribosomal S6 protein (S6RP) which is directly involved in modulation of protein synthesis (22), represents another protein sometimes described as a RSK substrate but wellestablished as phosphorylated by mTOR. Recent studies point to potential RSK involvement in direct S6RP enzymatic activation as well as indirect activation via phosphorylation of Raptor, a member of mTOR complex 1 (mTORC1) (23) . Therefore, to examine this signaling convergence node, we assessed the levels of S6RP phosphorylated on Serine 235/236. As shown in Figure 3B left panels, the levels of S6RP phosphorylation were not convincingly modulated by LJH685or LJI308, whereas both allosteric and catalytic mTOR inhibitors gave strong inhibition of S6RP phosphorylation ( Figure 3B , left panels). Interestingly, in both cell lines the combination of the AKT inhibitor or either of the mTOR inhibitors with LJH685 caused an additive inhibition of S6RP phosphorylation ( Figure 3B , right panels). These data suggest that RSK is a minor contributor and mTOR kinase a major contributor to phosphorylation of S6RP, but that YB1 is predominantly phosphorylated by RSK. We next examined the functional effects of LJH685 and, based on recent findings that implicate RSK in anchorage-independent growth modulation and cell transformation (24) assessed the effect of RSK inhibition in both attached and anchorage-independent cell culture settings. MDA-MB-231 and H358 cells were plated on conventional plastic tissue-culture plates as well as in soft agar and treated with increasing doses of LJH685. Cell proliferation was assessed using CellTiter Glo reagent and Alamar Blue stain for the two growth settings, respectively. YB1 phosphorylation was measured using the ECL assay in a parallel set of cells plated on plastic and identically treated with inhibitors as for the CellTiter Glo determination.
As Figure 4A demonstrates, the growth of both cell lines in soft agar was efficiently inhibited using LJH685, with EC 50 values of 0.73 μM and 0.79 μM in MDA-MB-231 and H358, respectively. Surprisingly, the growth of either cell line in an attached setting was only affected by LJH685 at concentrations significantly above the doses at which RSK is fully inhibited, with an EC 50 in this setting of 48 μM and 66 μM in these cell lines, respectively. The inhibition of YB1 phosphorylation tracked closely with the cell growth inhibition in soft agar setting, with EC 50 's of 0.39 µM and 0.57 µM in each cell line, demonstrating that RSK inhibition was fully achieved, irrespective of the differential growth response. In a control experiment, we confirmed that the concentration at which LJH685 inhibits pYB1 in the anchorage-independent setting correlates well with the concentration at which it inhibits pYB1 on plastic (Fig. S2) . The correlation of LJH685 EC 50 values for pYB1 & soft agar growth inhibition suggests that anchorage-independent growth in these cell lines is dependent on RSK kinase activity. In contrast, the inability of LJH685 to inhibit growth of the same cell lines on plastic indicates that in the attached growth setting, these cells do not depend on RSK function for proliferation. To further examine the signaling events underlying the differential growth effects of RSK inhibition, we utilized ultra-low bind cell culture plates which maintain anchorageindependent cell growth without a scaffold or matrix and serve as a basic three-dimensional surrogate system. This system possesses the advantage over soft agar in that it allows for sufficient cell recovery and protein extraction for analysis, and cells in this setting were similarly sensitive to RSK inhibitor (data not shown). MDA-MB-231 cells plated in the anchorageindependent setting or on conventional plastic plates were treated with LJH685, mTOR inhibitor or vehicle control DMSO for 4 hours, and the total cell lysates were analyzed for presence of phosphorylated and total S6RP and YB1 proteins using Western Blot. As shown in Figure 4B , YB1 phosphorylation was efficiently inhibited by LJH685 and was unaffected by RAD001 in either growth setting, confirming that in this cell line YB1 remains under the control of RSK and is not affected by mTOR activity in either attached or anchorage-independent growth settings. In contrast, LJH685 efficiently reduced phosphorylation of S6RP in the anchorage-independent setting. This suggests that S6RP becomes a RSK dependent substrate in the anchorageindependent setting and may be a critical mediator of the growth inhibition in soft agar.
To explore the possibility that there may be functional effects of RSK inhibition in additional cell lines, we assessed the effects of LJH685 across a panel of 21 cell lines derived from five lineages representing models of lung, colon, pancreatic, breast and melanoma cancers. differences in RSK inhibition responses, we used several other surrogate assays for anchorageindependent growth. H358 cells proved resistant to growing in a Matrigel matrix, but MDA-MB-231 cells could be grown in this matrix and exhibited 66% growth inhibition at 10 μM LJH685 with a concomitant morphology change in this setting ( Figure S3 ). This finding suggested that these cells remain dependent on RSK in this alternate anchorage-independent assay. We next tested MDA-MB-231 and H358 cell lines for RSK dependency while growing on Scivax NanoCulture assay plates. Scivax plates enable a low level of cell attachment due to a nano-scale pattern printed on the bottom of assay plates that promotes three-dimensional cell growth. MDA-MB-231 and H358 cells cultured for 10 days on Scivax plates grew as loosely adherent clusters of cells ( Figure 5A and Table S2 ). LJI308 was equally inhibitory to H358 growth in this setting as in soft agar, while MDA-MB-231 was less potently inhibited by LJI308 in this minimal-attachment setting.
Thirdly, we tested the effects of LJI308 on H358 and MDA-MB-231 cells in colony formation assays. This assay format tests the role of cell density in growth characteristics of cells by establishing sparse but attached growth conditions. As demonstrated in Figure 5B , H358 colony numbers were reduced more than 2-fold by a concentration of LJI308 that inhibits colony formation of these cells in soft agar. This result suggests that in addition to dependency on RSK for anchorage-independent growth, H358 cells are also dependent on RSK for growth on plastic when seeded at a low starting density. An alternative explanation is that RSK dependency in 
Aberrant activation of the MAPK & PI3K signaling pathways is a hallmark of many cancer types. Convergent signaling nodes between these pathways could present new targeting points to achieve an effective therapeutic outcome. RSK represents such a point of convergence by incorporating sequential activation steps from both ERK and PDK1 and by phosphorylating numerous downstream substrates associated with cell proliferation, motility and cell polarity (1, 2, 4, 5). However, our understanding of this critical signaling node has been previously hindered by the lack of potent and specific tools that enable a deeper understanding of RSK's role in cancer signaling networks. In this study we introduce two N-terminal RSK kinase inhibitors, LJH685 and LJI308, that are highly selective for all RSK isoforms. The selectivity of these inhibitors can possibly be explained by the compound's unusual propeller conformation that can be accepted by RSK's N-terminal kinase domain. The potency, selectivity, and effectiveness of LJH685 and LJI308 at inhibiting RSK activity in cells makes these molecules excellent new tools to better understand the role of RSK in MAP kinase pathway signaling and function.
We used LJH685 and LJI308 in functional cell viability assays in a panel of cell lines that bear activating mutations in the MAPK signaling cascade and are sensitive to MEK inhibitors. Surprisingly, LJH685 and LJI308 only inhibited the growth of a narrow sub-group of these cells, and only when these cells were grown in an anchorage-independent setting or at low cell densities in colony formation assays. Notably, while phosphorylation of YB1 at Ser102 was well-inhibited by LJH685 and LJI308, this did not closely correlate with widespread functional consequences. These results were surprising given recent studies that have linked YB1 to important physiological roles in cancer progression, including the expression of fibroblast growth factor receptor (FGFR), proliferating cell nuclear antigen (PCNA), MNK kinase and matrix metalloproteinase 2 (MMP2), among others (11, 12, 14, 28, 29 69  78  87  96  105  114  123  132  141  150  159  168  177  186  195  204  213  222  231  240  249  258  267  276 
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